Managing drug shortages during a pandemic: tocilizumab and COVID-19
- PMID: 33952621
- PMCID: PMC8177913
- DOI: 10.1503/cmaj.210531
Managing drug shortages during a pandemic: tocilizumab and COVID-19
Conflict of interest statement
Competing interests: Amol Verma and Fahad Razak are part-time employees of Ontario Health. Menaka Pai, Andrew Morris, Jennifer Gibson and Fahad Razak are members of the Ontario COVID-19 Science Advisory Table. Sally Bean and Jennifer Gibson are members of the Ontario COVID-19 Bioethics Table. Michael Fralick is a co-investigator for the SOLIDARITY clinical trial. He also received consultant fees from Pine Trees Health that has developed a CRISPR-based point-of-care diagnostic test for COVID-19. No other competing interests were declared.
Figures
References
-
- Bean S, Denburg A, Greenberg R, et al. Ethical framework for drug shortages that occur during the COVID-19 pandemic in Ontario. Toronto: University of Toronto Joint Centre for Bioethics; 2020. Available: https://jcb.utoronto.ca/wp-content/uploads/2021/04/Ethical-Framework-for... (accessed 2021 Apr. 23).
-
- Choe J, Crane M, Greene J, et al. The pandemic and the supply chain: addressing gaps in pharmaceutical production and distribution. Baltimore (MD): Johns Hopkins Bloomberg School of Public Health; 2020. Available: www.jhsph.edu/research/affiliated-programs/johns-hopkins-drug-access-and... (accessed 2021 Apr. 23).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources